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Abstract 
While the opioid crisis in the US has been widely publicized, what has not been given equal attention is the increasing 
number of pregnant women addicted to various prescribed and illegal opioids which has paralleled the current opioid 
epidemic. Instead of viewing the matter as a criminal justice issue, many experts believe that the issue is a public 
health problem because of the sheer number of people who are impacted nationwide, as well as the negative health 
consequences that affect the mothers and infants. We argue that opioid addicted pregnant women is not a criminal 
justice issue, but rather, a public health epidemic that requires healthcare approaches rather than punitive criminal 
justice strategies. 
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1. Introduction 
Recently, the Centers for Disease Control and Prevention (CDC), reported that opioid abuse in the US had reached 
epidemic proportions. More specifically, the CDC revealed that since 2015, there has been more than 33,000 deaths 
related to opioids, and another 91 people die each day because of opioid overdoses (Reddy et al., 2017). It also provides 
that the opioid crisis has been exacerbated because opioid prescriptions have quadrupled since 1999 making highly 
addictive drugs readily available (Rudd et al., 2016). But, why have opioids become so desirable? Pharmacologists 
argue that opioids are a classification of both natural and synthetic compounds that bind specific opioid receptors in the 
central nervous system to send messages to relieve pain, and in many cases, leave users with feelings of euphoria (Craig 
et al., 1994; Harvey et al., 1992). Nevertheless, vital statistics indicate that from 2000 to 2014, opioid related overdoses 
among adult Americans have increased by 200% (Rudd et al., 2016). Along with the increase in prescription opioid 
abuse, came a corresponding rise in heroin use, abuse, and overdose deaths (CDC, 2016). In addition, health experts 
noticed that by 2010, the socioeconomic and demographic characteristics of opioid addicts had changed in the US. 
According to Cicero and colleagues (2014), the majority of addicts that entered treatment programs were typically 
middle-class women who live in less urban or rural areas and over 90% were white. Nevertheless, while most people in 
the US are aware of the current opioid crisis, very few may know about the growing number of pregnant women who 
are addicted to opioids (including heroin) (Desai et al., 2014; Krans et al., 2015). More specifically, health experts argue 
that while efforts are made to inform the public about the dangers of opioids, more emphasis should be placed on one 
particular subset of the addicted population of users. In fact, health officials at the CDC provide that a large number of 
reproductive-aged women are at risk of developing opioid use disorder stemming from either prescription or illegal 
opioids since researchers revealed that over two-thirds (or roughly 66%) of pregnant women on medication-assisted 
treatment, and approximately 63% report a history of heroin use and intravenous heroin use, respectively (see Krans et 
al., 2015). Consequently, and more alarming is the fact that their newborns face serious health injuries associated with 
opioid abuse, namely drug withdrawal or Neonatal Abstinence Syndrome (NAS) (Reddy et al., 2017; Klaman et al., 2017; 
Patrick and Schiff, 2017).  
Health experts warn that in addition to other opioid addicts, the number of pregnant addicts has increased (Desai et al., 
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2014; Patrick et al., 2015). Some studies reveal that many women who were unaware of their pregnancy, later reported 
using various opioids. As a result, they unknowingly exposed their newborns to birth defects and themselves to serious 
harm (see Farst, Valentine, & Hall, 2011). Ko and colleagues (2017, p242), report that opioid exposure during 
pregnancy can occur for several reasons that include: use of clinically-approved prescriptions of opioids for pain relief, 
misuse or abuse of prescription opioids, use of illegal drugs (namely, heroin), or medication-assisted treatment of opioid 
use disorder (also see ACOG, 2012). Because scant attention has been devoted to pregnant opioid addicts, this 
investigation is divided into four parts. Part One presents the nature and extent of pregnant opioid addicts in the US. 
Part Two addresses why pregnant opioid addiction is a public health, rather than a criminal justice issue. Part Three 
offers prevention and treatment approaches to this growing epidemic. Part Four presents viable policy implications. In 
the final analysis, we argue that the use of public health or epidemiological approaches to treat this special population of 
opioid addicts is more effective at reducing the negative health consequences associated with this addiction. 
2. The Nature and Extent of Opioid Addicted Pregnancies 
Research shows the number of opioid addicted pregnant women has skyrocketed and reached the point of crisis in the 
US, especially in the last decade, leading health officials to label the matter an epidemic (Krans and Patrick, 2016; 
Patrick and Schiff, 2017). As such, public health experts estimate that between 400,000 and 440,000 infants are 
negatively affected by prenatal alcohol or illegal drug exposure that often leads to health problems (Cohen, 2017; 
Swanson, 2014). Correspondingly, studies report that every 25 minutes, a drug addicted baby is born in the US (Cohen, 
2017). Moreover, Desia and colleagues (2014), research reflects that records from Medicaid enrolled women show an 
increase in the percentage of pregnant women who filled at least one opioid prescription (Also see Ailes et al., 2015). 
Furthermore, Reddy and colleagues (2017, p10), find that approximately one third of insured reproductive-age women 
(e.g., between the ages of 15 and 44) fill a prescription for an opioid medication annually, while a woman seeks care in 
an emergency room for misuse of prescription opioids every three seconds in the US (see also CDC, 2017). Ailes and 
colleagues (2015, p37), present a more persuasive argument by reporting that between 2008 and 2012, an average of 39% 
of Medicaid insured, and 28% of privately insured women of reproductive-ages filled an outpatient prescription for an 
opioid each year. These patients with prescriptions were disproportionately non-Hispanic whites living in the southern 
states. Accordingly, they argue that the over prescribing of opioids that began in the latter 1990s, led to the escalation of 
use among pregnant women (Ailes et al., 2015). Moreover, reports reveal an increase in opioid use among pregnant 
women from 2000 to 2010 by an estimated 23% from 18.5% to 22.8%. Likewise, research by Maeda and colleagues 
(2014), focused on the prevalence of opioid abuse among pregnant women, revealed an increase from 1.7 per 1,000 
delivery admissions in 1998 to 3.9 in 2011. Strikingly similar to these statistics, Swanson (2014), and the CDC (2016), 
reported that the use and misuse of opioids (e.g., codeine, hydrocodone, fentanyl, morphine, opium, methadone, 
oxycodone, meperidine, hydromorphone, propoxyphene, and buprenorphine) by pregnant women underwent a dramatic 
increase from 1.2 per 1000 hospital live births in 2000 to 5.6 in 2009, while NAS incidences increased from 1.2 to 3.4 
per hospital live births (also see Patrick et al., 2015; Patrick et al., 2012).   
Another study reported that opioid use among pregnant women resulted in an alarming 400% nationwide increase in 
NAS cases and other health complications. More specifically, where NAS is concerned, data revealed an increase from 
1.2 per 1,000 hospital births in 2000 to 5.8 in 2012, while some states reported rates that exceeded 30 per 1,000 hospital 
births. However, by 2012, medical records from several states showed on average, one NAS affected baby was born 
every 25 minutes in the US (see Patrick et al., 2015; Also see Ko et al., 2016). Furthermore, Swanson (2014), cited two 
studies that reported opioid use and abuse has been on the rise among pregnant women. The first revealed that 23% of 
1.1 million pregnant women on Medicaid filled an opioid prescription in 2007. This represented an increase from 18.5% 
in 2000. The second reported that 14% of privately insured pregnant women also filled a prescription for opioids. 
Swanson (2014), contends that what is more alarming about doctors prescribing pain medications to pregnant women is 
the fact these doctors are aware that they may cause birth defects.     
Ailes and colleagues (2015), provided demographic data on reproductive-aged women with outpatient claims for using 
either private or Medicaid service for an opioid prescription during 2008-2012. These data focused on variables such as 
age group, geographical region (only available for privately insured women), and race and ethnicity (only available for 
Medicaid enrolled women). More specifically, with respect to those privately insured, from 2008-2012, between ages 
15-19, the average was 20.4. Recipients between ages 20-24 average was 23.8. Those between ages 25-29 average was 
29.6. Those between ages 30-34 average was 30.9. Recipients between ages 35-39 average was 30.4, while those 
between ages 40-44 average was 29.9. Where geographical region is concerned for the same period (2008-2012), 
recipients in the Northeast average was 21.8. Those in the North central average was 25.4. Those from the South 
average was 31.5. Those from the West average was 26.6, and the unknown regions comprised 27.3. Data regarding 
race and ethnicity was not available for those who were privately-insured. By comparison, data on those who received 
Medicaid during 2008-2012, revealed that the average was 25.9 for those ages 15-19.  Recipients between ages 20-24 
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had an average of 41.7. Those between ages 25-29 average was 46.6. Those between ages 30-34 average was 48.7. 
Recipients between ages 35-39 average was 50.6, while those between ages 40-44, average was 52.5. Data on 
geographical region were not available for those who received Medicaid. However, data regarding race and ethnicity for 
the same period (2008-2012), revealed that Whites, non-Hispanic average was 46.4. Blacks, non-Hispanic average was 
35.2. Hispanics average was 33.6, and Others average was 28. Stated differently, data confirm that women of all races 
and ethnicities that lack private insurance are impacted by the opioid crisis.      
3. Pregnant Opioid Addicted Mothers: A Criminal Justice or Public Health Issue 
3.1 A Criminal Justice Issue 
While public health officials view opioid addiction as a disease that should be treated, law enforcement officials, and 
other criminal justice practitioners, see drug use as a violation of the criminal law that must be punished (see Gaines and 
Kraska, 1997; Tonry and Wilson, 1990). Therefore, many in the justice system believe that opioid users should be 
convicted under existing drug and child abuse laws, and then receive a prison sentence at an appropriate correctional 
facility (Peak and Everett, 2017). More specifically, justice officials believe that when addicted mothers expose unborn 
children to illegal drugs, it constitutes either felony aggravated assault; causing harm to an unborn fetus; engaging in the 
chemical endangerment of a child, or when the fetus dies, a homicide (Paltrow and Flavin, 2013). However, states vary 
with respect to which charges it will file against the accused. Nevertheless, most states view drug use during pregnancy 
as grounds for sentencing the mother to a term of imprisonment. Other states may justify involuntary detainment for 
inpatient treatment, and some states may even impose civil commitment (Vestal, 2017). Most justice critics view these 
reactions as ways that states punish mothers and children (Cohen, 2017). Despite the current opioid crisis, and the 
corresponding number of pregnant women who engage in substance use disorder of legal or illegal opioids, most states 
typically respond in a punitive way.  
Justice experts believe that prosecuting and incarcerating pregnant opioid users will deter them, and others, from using 
(Hunter, 2017; Patrick and Schiff, 2017). Critics ponder whether this means that the mothers of the estimated 440,000 
babies born addicted to drugs each year will be arrested and held criminally responsible. The same group argues that 
this approach will not achieve deterrence, but rather, will cause the opposite effect (Roberts and Nuru-Jeter, 2010). 
Nevertheless, justice officials advocate the criminalization of drug users without regard to their pregnancy status. 
However, they argue that being an addict (e.g., the status of addiction) is not criminalized, but instead, the behaviors 
that addicts engage in such as buying, receiving, and exposing unborn babies to drugs that could cause birth defects, 
chemical shock from opioid withdrawal, or an untimely death, constitutes criminal law violations. On the contrary, 
those with opposing views, argue that this approach exacerbates the problem and discourages addicted pregnant women 
from seeking prenatal care or substance abuse treatment since they fear arrest, detention, and prosecution (Peak and 
Everett, 2017; Patrick and Schiff, 2017). As such, reports show that the fear of punishment, along with the prospect of 
losing a newborn, have frightened many addicted pregnant women to the point where they avoid visiting hospitals, and 
instead, are having babies at home, in cars, and on the side of the road. These critics believe that this trend will likely 
continue since an estimated forty-five states require mandatory reporting (to police and child protective services) if drug 
use is detected from tests taken by pregnant women, or if babies are born addicted to opioids (Hunter, 2017; Cohen, 
2017).  
3.2 Efforts toward Massive Confinement 
Correctional statistics reveal that despite a slight decline (0.9%) in its prison population, the US is still the most punitive 
nation among advanced societies since it incarcerates and provides supervision to an estimated 6,613,500 Americans 
annually. This includes pregnant women, some of whom have extensive histories of substance abuse (Kaeble and 
Cowling, 2018; Krisberg, Marchionne, & Hartney, 2015; Seiter, 2014). Many offenders are housed in the nation’s jails 
and prisons, while the vast majority of offenders are given community supervision (e.g., probation or parole). Some 
scholars argue that many incarcerated offenders are residual leftover from the crack cocaine war fought during the 
1980s and 1990s which has contributed significantly to prison overcrowding (see Messner and Rosenfeld, 2013; also 
see Mauer, 2006). Similarly, experts fear the current opioid crisis, combined with many states’ punitive stance on 
pregnant opioid users, will add to an already strained correctional system (e.g., sentencing more addicted pregnant 
offenders to prison) that claims to be seeking strategies to alleviate overcrowding problems through criminal justice 
reforms. Observers note that talk of criminal justice reform has not resulted in legislation to decongest the nation’s 
overcrowded places of confinement. Currently, most states regard pregnant opioid addicts as offenders who committed 
assault on their unborn child and consequently, deserve punishment, rather than treatment for their addiction (Patrick 
and Schiff, 2017). It bears mentioning that offenders who are sentenced by the justice system and remanded to 
institutional corrections (e.g., jails and prisons), are sent to places that focus on meting out punishment instead of 
providing treatment. Some justice scholars argue that this may explain the high rates of recidivism since it is unlikely 
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that offenders will receive treatment for opioid or any other chemical dependency. Moreover, the alternative form of 
corrections is community-based. It is unlikely and unwise that addicted offenders will be released back into the free 
community where they will have easy access to illegal drugs. Therefore, critics argue the justice system is not designed 
for drug treatment or to provide the level of medical care needed by offenders in general, and pregnant women and their 
unborn children, in particular. 
3.3 Confined Women and Healthcare  
The need for substance abuse treatment for confined women is well-documented in the criminal justice literature since 
research shows that an estimated 49% have serious histories and problems with alcohol and substance abuse prior to 
incarceration (Calhound et al., 2010; Krisberg, Marchionna, & Hartney, 2015; Bloom and Owen, 2002). Similarly, 
Mumola and Karberg (2004), reported that 59% of female state prisoners admitted to using drugs within a month of 
committing their offense. Moreover, 17% reported using methamphetamines in the month of their crime. Likewise, 
Green and Snell (1999), reported that 40% of women were under the influence of drugs at the time they committed their 
crime. Some experts argue that many women who commit crime often come from abusive backgrounds which 
invariably leads them to drug abuse and addiction as a coping mechanism (Covington, 2007). To further highlight the 
point, a nation-wide study found that one in three women in state prisons reported that they committed the crime that 
landed them in prison to get money needed to defray the cost of their drugs. Notwithstanding, an investigation 
conducted in Maryland by the Center for Substance Abuse Treatment (1997, p2), reported that nearly 80% of the 
women in state prisons have “severe, long-standing substance abuse problems.” These findings reveal that women in 
prison need substance abuse treatment programs. While some prisons offer drug programs, research consistently shows 
that they are inadequate, unsatisfactory, and highly ineffective since many women offenders often recidivate after 
release owing to committing a drug offense. Furthermore, Stephan (2008), reported that while 74% of all prisons 
offered drug and alcohol counseling in 2002, only 12.9% of the prison population participated in drug treatment 
programs. Similarly, Karberg and James (2002), reported that only 20% of women offenders reported receiving drug 
treatment during their incarceration. A later follow-up by Scroggins and Malley (2010), revealed that women prisoners 
are still not receiving needed treatment programs while incarcerated. Consequently, as part of their post-incarceration, 
they typically are placed in substance abuse programs that are often insufficient to help them successfully reenter 
society. Because of this, some justice scholars have advocated an increase in more and better-quality treatment 
programs for women in and outside of prisons. Research by Chesney-Lind and Pasko (2004), and Patrick and Schiff 
(2017), is instructive in this regard. Their work suggests that substance abuse treatment programs must be gender 
specific and focus on strategies that address women’s substance abuse problems.              
While nearly every state in the country is affected by the current opioid epidemic, research shows that North Carolina 
has been one of the most adversely impacted by this crisis. Therefore, it offers a timely as well as realistic example of 
the economic devastation that some states are experiencing since experts report that in 2014, the total costs of the opioid 
crisis to North Carolina reached an estimated $2 billion: $582 million in health care costs from opioid abuse, and $1.5 
billion in loss of future productivity and medical costs from overdose deaths (Hunter, 2017). Furthermore, North 
Carolina spends an estimated $32,594 annually to incarcerate offenders. With the influx of more opioid addicts being 
brought into the justice system (including pregnant women), this will invariably cost the state more monies to support 
its public health as well as criminal justice systems. North Carolina can be an example to other states that are being 
confronted with the opioid epidemic.    
3.4 A Public Health Issue 
The increase in opioid addicted pregnant women is a public health issue because of the negative health consequences 
associated with the behavior. As stated earlier, the CDC, along with other health professionals, have labeled the matter 
an epidemic that should be addressed by the healthcare professionals, and not criminal justice officials for two reasons. 
First, opioid abuse is a serious public health problem because the number of addicts has reached epidemic proportions 
(with it a host of health concerns that could impact the population at-large). Second, opioid addiction is a disease that 
must be addressed by trained medical professionals. More specifically, health officials argue that agents of the justice 
system are experts at arresting, charging, and punishing offenders, but not at making medical diagnoses, providing 
medical treatment, and monitoring opioid addicts since they lack medical training, expertise, and the resources needed 
to adequately treat the effects that prescription and illegal opioids have on pregnant women and their unborn children 
which typically include: Opioid use disorder (OUD), NAS, HIV/AIDS, Hepatitis C, and other infections common to 
intravenous drug users (CDC, 2015). Because more people could be exposed to these and other diseases that can 
quickly spread throughout the community, the effects of opioid addiction are a public health issue. Stated differently, the 
consequences of opioid addiction (prescribed or illegal) in general, and to pregnant women and their unborn children, in 
particular, transcends the scope, expertise, and resources of the justice system because they are far reaching and could 
have negative health consequences on the broader community and society. 
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3.5 Opioid Use Disorder (OUD) 
Research shows that OUD has reached the point of crisis in the US (Bianchi, 2017; Patrick and Schiff, 2017). Health 
professionals argue that the problem is more likely to increase in the future. Therefore, they suggest that efforts should 
be made to treat and manage these conditions. They also argue that more research should be conducted to identify and 
improve the health outcomes of opioid addicted pregnant women and their new born infants. More specifically, health 
experts recommend that pregnant women receive routine screening for substance use, including misuse of prescription 
and illegal opioids (namely, heroin) throughout their pregnancy. They also suggest as a matter of standard therapy for 
opioid addicted pregnant women that medical experts (because these medications are considered low risk and will 
improve compliance to prenatal care), consider opioid replacement therapy such as methadone or buprenorphine to 
manage withdrawals, reduce cravings, and prevent illicit opioid use, as well as provide medical supervision for 
withdrawal (Bianchi, 2017).      
3.6 Neonatal Abstinence Syndrome (NAS) 
NAS is a hidden consequence of the opioid crisis (Ko et al., 2017). It occurs in women who use opioids during 
pregnancy. Moreover, being addicted to opioids and pregnant increases the likelihood that NAS and other health 
complications will surface (Patrick and Schiff, 2017; Brocato, 2015). Health experts define NAS as a drug withdrawal 
syndrome that typically occurs in infants after in-utero exposure to opioids. Some research shows that it appears within 
2 to 3 days after birth and reveals itself with adverse impact on the central and autonomic nervous systems via 
irritability, gastrointestinal dysfunction, and temperature instability (Ko et al., 2017; Reddy et al., 2017; Bagley et al., 
2014). Other studies suggest the effects often include: tremors, diarrhea, incessant crying and irritability, along with 
problems sleeping, feeding, and breathing (Bianchi, 2017; Brocato, 2015). Unfortunately, some other health issues NAS 
babies experience are respiratory problems, feeding abnormalities, low birth weight, and seizures that are very costly to 
parents, as well as hospitals. This is especially true for neonatal intensive care units (Ko et al, 2017). In fact, experts 
estimate that in 2012, children born with NAS cost hospitals an estimated $1.5 billion with approximately 80% paid for 
by Medicaid programs. Consequently, public health officials argue that steps must be taken to prevent and treat pregnant 
opioid addicted women before and during pregnancy in order to reduce incidence of NAS and prevent its economic 
impact on the health care system. They also suggest opioid exposure during pregnancy could occur for many reasons 
that include: clinician-approved prescriptions given for pain relief; treatment given to opioid addicted mothers for 
prescription opioid, illegal use of opioids (e.g., heroin), or from medication-assisted treatment for opioid use disorders 
(Bianchi, 2017; Ko et al., 2017, p242).  
3.7 HIV/AIDS and Hepatitis C (HCV) 
Statistics also reveal other health concerns that opioid addicted pregnant women could face. Data reveal increasing 
numbers of pregnant women who contract HIV/AIDS and Hepatitis C (HCV) from engaging in high risk behaviors such 
as sharing contaminated syringes or having unprotected sex with others who are infected with these and other infectious 
diseases (Alcabes and Friedland, 1995; Steedman and Younoussi, 2000). Health experts report the former typically 
occurs when addicts inject illegal opioids such as heroin. Nevertheless, McCance-Katz (2011), reports that caring for 
pregnant women with HIV/AIDS who also suffer from co-occurring substance abuse, presents a medical challenge since 
effective clinical care requires interventions that must focus on both the physiological changes of the women, and the 
needs of their developing fetus. This is vitally important since opioid dependent women need opioid therapies (such as 
methadone or buprenorphine). These women also face the risk that drug interactions with some HIV medications could 
cause adverse effects that led to negative outcomes. Further, McCance-Katz provides that the main goals of treatment 
are twofold. First, to ensure a safe pregnancy for the women. Second, to avoid fetal toxicity by delivering babies that 
are free of HIV. Health experts argue that such goals require aggressive treatment to the HIV in order to decrease rival 
load, or prevent transmission to the fetus, as well as protect the mother from any infections owing to immune 
deficiencies induced by HIV (Also see McCance-Katz et al., 2009). Moreover, Jones and colleagues (2005), report that 
opioid addicted pregnant women should be treated at methadone maintenance treatment programs to protect them from 
complications associated with injection drug use. These researchers recommend that these pregnant women be given 
buprenorphine because studies report that it has fewer adverse effects and is linked to fewer cases of severe NAS than 
methadone (ACOG, 2012).     
3.8 Epidemiological Approaches to Public Health Issues  
Public health officials use the epidemiological approach which consists of health-event surveillance, epidemiological 
analysis, intervention design, and evaluation to prevent illnesses and injuries (Schneider, 2011). Because of past successes 
with treating and curing diseases and injuries, officials at the CDC are confident that the epidemiological approach can 
also be successful at preventing and curing the increasing population of opioid addicted pregnant women. Again, opioids 
are defined as a class of drugs that includes illicit heroin, but also prescription pain relievers (National Institute of Drug 
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Abuse, 2015). The epidemiological approach employs a multi-disciplinary approach to study and prevent diseases and 
injuries that adversely impact the population. Because of the complexities of diseases and injuries, the approach draws on 
the resources of multiple disciplines to better understand and address the issues of drug use, addiction, and in this case, 
how they impact pregnancy. Some disciplines used in the epidemiological approach include: biomedical sciences; 
environmental health sciences; social sciences; and the behavioral sciences (Schneider, 2011).  
As a strategy, epidemiologists rely on public education campaigns to reach millions of Americans who often represent a 
captive audience. As such, they use television, radio, and billboards to inform and educate people about pressing health 
concerns (Schneider, 2011; Rosenberg and Fenley, 1991). They provide information on disease prevalence and incidences, 
where to seek treatment and help for (in this case) opioid addiction (from either prescription painkillers, or heroin) used by 
pregnant women. Moreover, this approach allows public health officials to treat diseases and injuries as epidemics when 
many people in the population are affected. For example, Cohen (2017), and Swanson (2014), reported an estimated 
400,000 to 450, 000 babies are born addicted to opioids. Relying on the epidemiological approach enables public health 
officials to mobilize resources in medicine, mental health, social sciences, and substance abuse services to prevent injuries 
and death (Rosenberg and Fenley, 1991). Medical experts argue that this approach is a radical departure from strategies 
used by the criminal justice system to control crime. Therefore, epidemiologists represent a coalition of professions united 
by their shared mission and focus on disease prevention and health promotion. As part of their prevention efforts, 
epidemiologists search for common exposures and shared characteristics among people who are sick or affected by drug 
use and addiction to seek causative measures. More specifically, public health experts, use a five-step approach to address 
health problems in the community. They seek to: (1) define the health problem, (2) identify the risk factors associated with 
the problem, (3) develop and test community level intervention to control or prevent the cause of the problem, (4) 
implement interventions to improve the health of the population, and (5) monitor the interventions to assess their 
effectiveness (Schneider, 2011, p11-12). These measures are used to develop interventions to prevent undesirable health 
outcomes that have been identified either via surveillance by health officials or from community concerns related to 
health matters such as an increasing number of opioid addicts (including pregnant women).   
Public health officials, as well as epidemiologists employ a systematic approach to address health problems. They design 
strategies of intervention to prevent undesirable health outcomes. They typically prevent illnesses and accidents by using 
a three-prong approach that includes: Primary prevention, secondary prevention, and tertiary prevention. First, primary 
prevention seeks to avoid the illness or occurrence by preventing exposure to risk factors. This occurs when health 
officials inform women about substance and opioid misuse before pregnancy. Moreover, it seeks to reduce the abuse of 
prescription opioids via monitoring, ensuring that unused opioids are disposed of and provide police with tools needed to 
stop illegal prescription writing. Public health officials typically engage in educational campaigns by using television, 
radio, and billboards to warn the public about the dangers associated with prescription and illegal opioids (e.g., heroin). 
For example, they may target OUD, HIV/AIDS, HCV, NAS, or other consequences from engaging in risky behavior. Next, 
secondary prevention seeks to minimize the severity of the illness or damage due to the injury causing event after it has 
occurred. This occurs when health officials provide opioid users the treatment they need before they become addicted to 
prescription or illegal heroin which could produce negative health consequences for pregnant women, as well as their 
unborn child. This effort may require early identification of illicit substance use during pregnancy. It is necessary to 
improve the health outcomes for mothers and their unborn infants. Experts also recommend the use of routine screening 
for drug use during pregnancy. Finally, tertiary prevention focuses on minimizing disability by providing medical care 
and rehabilitation services (Schneider, 2011, p12). Because pregnant women with OUD often face preterm labor, fetal 
distress, or fetal death, health providers argue they should be given opioid agonist therapy or medication assisted 
treatment with methadone or buprenorphine since it is considered as standard treatment. These treatments help mothers 
and infants by: stabilizing fetal levels or opioids, reduce repeated prenatal withdrawal, bring mothers inline for treatment 
of infectious disease such as HIV, HBV, HCV, and reduce the likelihood of transmitting these to unborn infants, and 
ultimately, improving the long-term health outcomes for both mother and baby (NIH, 2017). Public health officials are 
committed to providing treatment to pregnant women, their unborn infants, and others who may have an illness linked to 
legal or illegal opioids.   
4. Prevention and Treatment 
Healthcare experts suggest that successful efforts at preventing and reducing incidence of NAS can be achieved as part 
of primary prevention strategies. According to Ko and colleagues (2017), primary prevention techniques to prevent NAS 
must focus on a twofold approach:  responsible opioid prescribing and providing users with access to preconception 
care and family planning services. First, where responsible opioid prescribing is concerned, experts at the CDC 
recommend that clinicians be aware of the sensitive nature of prescribing opioid medications to pregnant and 
nonpregnant women at reproductive age. Furthermore, the CDC recommends that clinicians disclose the long-term 
effects of opioid use to patients with regard to their current and future pregnancy. Similarly, Dowell, Haegerich, & Chou 
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(2017), reported that the CDC has issued guidelines specifying a protocol that clinicians should follow when prescribing 
opioids to pregnant women. One recommendation is that clinicians and patients fully consider the risks and benefits 
before deciding whether to use opioid therapy for chronic pain during pregnancy. Another recommendation is that 
women of reproductive age strongly consider using nonopioid pharmacologic therapy to manage chronic pain. The 
CDC also advises that when opioids are used, clinicians should prescribe the lowest effective dosage (Dowell et al., 
2017). Second, family planning services are also recommended as a primary prevention strategy that might help prevent 
and reduce incidence of NAS (Gavin et al., 2014). Research shows that the CDC recommends that access to family 
planning and preconception care is provided to women of reproductive age. In their investigation, Gavin and colleagues 
(2014), found that among women who abused opioids, 86% reported that their pregnancy was unplanned. Because of 
this, public health officials at the CDC and the Office of Population Affairs of the U.S. Department of Health and 
Human Services recommend that healthcare providers encourage the use of family planning services that offer an array 
of options that include: preconception services, pregnancy intervention screening, and contraceptive counseling to 
prevent unintended pregnancy.          
Health officials suggest that women with OUD (including pregnant women), can be provided intervention treatment 
strategies. As such, the Substance Abuse and Mental Health Services Administration and the American College of 
Obstetricians and Gynecologists recommend that pregnant women who suffer from OUD begin medication for 
addiction treatment (MAT) with methadone or buprenorphine. These same officials argue that both therapies have been 
shown to be safe and effective treatments for pregnant women who suffer from OUD (see Jones et al., 2018; Klaman et 
al., 2017). While this is suggested, health officials warn that clinicians should evaluate the effects of concurrent 
substance use (Smith, Costello, & Yonkers, 2015). Moreover, they advise that because the likelihood is greater that 
these women will give birth to babies with NAS (though it is less severe than in the absence of treatment), they should 
seek collaboration with pediatric care teams to determine if infants suffered utero opioid exposure so that appropriate 
treatments can be provided (Smith et al., 2015; Klaman et al., 2017).  
Health experts report the effects of NAS can be mitigated with the appropriate strategies. For example, some health 
officials suggest that mitigation can be achieved through improvements in identifying infants who are at risk and 
standardizing the treatment process of infants with NAS. For example, Ko and colleagues (2017), reported that states 
such as Florida, Tennessee, Kentucky, and Georgia are leading the way in this effort since they require that all cases of 
NAS are quickly reported to the state health department. Health experts believe that this strategy will enable states to 
identify and provide interventions to access locations where high incidence of NAS are reported. Consequently, this will 
mitigate the effects of NAS and reduce the economic burden associated with them.    
Research suggests that treating NAS should start with nonpharmacological strategies that include: minimizing 
environmental stimuli, careful swaddling, and breastfeeding (when no other contraindications are used) (see Hudak and 
Tan, 2012). Moreover, to ease the infants’ withdrawal from severe cases of NAS, some health professionals and the 
American Academy of Pediatrics recommend tapered dosages of morphine or methadone be used in conjunction with 
nonpharmacological strategies (Hudak and Tan, 2012). In addition, other research suggests that the use of family 
involvement or “rooming” with NAS infants instead of placing them in neonatal intensive care units can decrease the 
length of hospital stays needed for pharmacological treatment (Patrick et al., 2016). Additionally, in a meta-analysis, 
Klaman and colleagues (2017), used data from three separate search methods to: (1) identify peer reviewed journal 
articles that focused on evidence of treatment methods for pregnant or nonpregnant women with opioid use disorder 
(OUD). They excluded from the analysis: (1) review articles that focused on primary publication, (2) commentaries, and 
(3) articles that did not focus on opioid use and misuse among pregnant women, or those that did not provide the effects 
of prenatal OUD on children. More specifically, the analysis examined studies that were conducted from 1975 to 2015. 
A total of 75 articles (n=75) were used to identify evidence regarding treatment given to pregnant and parenting women 
with OUD and its effect on their infants and children. The authors stated that most of the literature addressed the use of 
methadone and buprenorphine. The study focused on three areas: (1) prenatal, (2), postnatal, and (3) neonatal. In the 
final analysis, the study revealed that buprenorphine treatment of OUD during pregnancy resulted in lower risk of 
preterm births, greater weight, and larger head circumference compared with the use of methadone treatment. Despite 
this finding, the study suggested that ongoing research on the prenatal, postnatal, and neonatal periods is needed to 
better understand the complexity of treating OUD among pregnant and nonpregnant women. 
In another research investigation by Jones and colleagues (2008), that addressed questions faced by clinicians 
confronted with treating pregnant patients addicted to opioids, the study reports that much has been learned about 
treating this special population in the last forty years since clinicians now prescribe both methadone and buprenorphine 
to these patients. They concluded that methadone maintenance, more so than medication-assisted withdrawal is more 
effective at preventing relapse since it reduces fetal exposure to illicit drug use and neonatal outcomes. In the end, they 
argued that the Maternal Opioid Treatment Human Experiment Research (MOTHER) study that began in 2005 which 
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compares the safety and efficacy of methadone and buprenorphine provides more evidence-based data needed to guide 
optimal treatment approaches for opioid dependent pregnant patients.           
5. Policy Implications 
Because the opioid epidemic affects the entire nation, treatment and prevention efforts must be initiated at the local, 
state, and federal levels by policy-makers and elected officials (Krans and Patrick, 2016). Realizing the enormity of the 
problem, especially the negative health consequences such as addiction, birth defects, and untimely deaths, the House of 
Representatives recently passed the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment 
(SUPPORT) for Patients and Community Act to fight the opioid crisis. The bill specifies that monies should be allocated 
in several areas that include: (1) expanding access to treatment and recovery services; (2) creating opioid alternatives to 
pain treatment, and (3) intercepting illegal opioids at mail facilities and combating fentanyl. This bill, along with $5 
billion from the Comprehensive Addiction and Recovery Act and the 21st Century Cure Act (2016) are steps in the right 
direction to combat the current drug war. Now, the bill must pass through the Senate and be signed by the President in 
order to become law. Hopefully, funding from these two sources will be received on the local and state levels and used 
for providing treatment and therapy to those adversely affected by prescription and illegal opioids (including pregnant 
addicts). Moreover, health experts report that studies reveal that the epidemic proportions of opioid cases, including 
addicted pregnant women and increases in NAS cases have come to the attention of healthcare providers, the public, and 
policy-makers (Patrick and Schiff, 2017). As a result, health experts recommend that policies created to help opioid 
addicts in general, and addicted pregnant women in particular, should be designed to increase accessibility and 
affordability of substance abuse treatment services since research reports that access to treatment for maternal OUD and 
standardized treatment for infants with NAS could help decrease the effects of NAS (Ko et al., 2017). 
Our policy recommendations are sevenfold and consistent with those provided by Patrick and Schiff (2017, p4). They 
include the following: (1) educating the public about the addictive and dangerous potential of prescription and illegal 
opioid use, namely heroin (e.g., addiction and other risky behaviors), (2) providing evidence-based treatment to 
pregnant women who suffer from substance abuse disorder, (3) increasing access to reproductive health services, (4) 
implementing early universal substance screening for all pregnant women (in order to early identify anomalies in the 
fetus, (5) providing access to improved prenatal care for pregnant women with substance use disorders (to include 
medication-assisted treatment programs such as methadone or buprenorphine), and gender specific substance treatment 
programs, (6) informing healthcare providers (who care for women about states mandatory reporting laws’ regarding 
drug use and pregnancy, and (7) allocating appropriate funds for social support services and child welfare systems 
charged with providing care to infants who are exposed to substances. We argue that these policies will effectively 
address opioid addicted pregnancies as a public health issue.    
Consistent with the public health approach, we recommend the use of the epidemiological or multidisciplinary approach 
to treating and preventing opioid use and its consequences among pregnant women. As such, we argue that long-term 
follow-ups with this special population of opioid abusers should involve medical, developmental, and social service 
agencies. We believe that a coordinated multidisciplinary approach is more likely to improve the health outcomes for 
infants and mothers than punitive criminal justice responses since this methodology has achieved success with other 
health problems in the past (Also see ACOG, 2017).  
At the same time, efforts need to be made nationally to decriminalize pregnant women who are addicted to opioids 
(Kremer and Arora, 2015). As revealed in this investigation, it is common knowledge that many pregnant opioid addicts 
are willing to risk their health and the lives of their unborn children to avoid being punished by the justice system. 
These women typically fear being sent to prison or having their children legally removed from their custody after birth. 
Thus, this punitive measure is believed by some experts to exacerbate the problems faced by opioid addicted pregnant 
women. To that end, creating the aforementioned health policies will require a paradigm shift from thinking about 
opioid addicted women as drug abusers to accepting the National Institute on Drug Abuse’s (NIDA) definition of 
addiction as a chronic disease that can be successfully treated and managed (NIDA, 2010). Stated differently, pregnant 
opioid addicts must be viewed as women with a treatable disease who need treatment and not punishment. More 
specifically, NIDA also advises that treating substance use disorders successfully requires social support, 
patient-provider rapport, and access to treatment.     
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